BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

CureVac GmbH 

Paul-Ehrlich-Str. 15

Tübingen    72076  Germany
Phone: 49-7071-92053-0 Fax: 49-7071-92053-11


SEARCH JOBS


Industry
Biotechnology






 Company News
CureVac GmbH Completes Patient Recruitment For Phase 2 Clinical Trial Of Mrna-Based Prostate Cancer Treatment 12/16/2013 9:26:35 AM    More...
CureVac GmbH Release: 1st International mRNA Health Conference in Tuebingen Heralds a New Era in Modern Medicine 11/5/2013 8:48:26 AM    More...
CureVac GmbH Collaborates With the Cancer Research Institute and Ludwig Institute For Cancer Research (LICR) to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer 11/4/2013 10:37:24 AM    More...
CureVac GmbH to Collaborate With Janssen Pharmaceutical Inc. of mRNA-Based Influenza Vaccine 10/3/2013 9:03:59 AM    More...
CureVac GmbH Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer 3/27/2013 8:03:13 AM    More...
Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac GmbH's RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection 11/26/2012 9:20:44 AM    More...
CureVac GmbH Secures $104 Million in Series D Financing 9/18/2012 6:34:58 AM    More...
CureVac GmbH, Sanofi Pasteur (SASY.PA) and In-Cell-Art Collaborate on a $33.1 Million Project Co-Funded by the U.S. Defense Advanced Research Projects Agency; Deal Projected to be Worth €150 Million-plus 11/15/2011 6:16:19 AM    More...
CureVac GmbH Presents Results of a Phase I/IIa Trial in Non-Small Cell Lung Cancer (NSCLC) with CV9201, an mRNA Based Cancer Vaccine, at the 26th Annual SITC Meeting in Washington 11/7/2011 9:04:47 AM    More...
CureVac GmbH Presents Convincing Data from the First Ever Phase I/IIa Clinical Study With a mRNA Based Vaccine 10/4/2010 2:20:17 PM    More...
12

//-->